Claritas Pharmaceuticals Inc CLAZF

Healthcare Biotechnology

Claritas Pharmaceuticals, Inc., formerly Kalytera Therapeutics Inc, is a biotechnology company that is focused on developing R-107 for the treatment of vaccine-resistant coronavirus disease (COVID) strains. The Company’s products in development include R-107 for coronavirus disease and Viral Infections, R-107 and Vaccines, and CLA-1816 for treatment of pain. R-107 is designed to defeat COVID viruses on contact. R-107 targets the Achilles heel of COVID, the spike protein on the surface of the virus. R-107 releases nitric oxide, which attaches to a specific amino acid on the spike protein, thereby disabling the spike protein. The CLA-1816 provides effective pain reduction, without the risks of addiction or respiratory suppression that exist with opioid analgesics. CLA-1816 strongly binds with and activates the alpha3 glycine pain receptor in the spine. The Company has leased a laboratory, office, and archival space in Beverly, Massachusetts.

GREY:CLAZF - Post by User

Claritas Pharmaceuticals Inc > Get Ready Gentlemen !!

<< Previous

Bullboard Posts

Next >>

Comment by MyKnighton May 25, 2020 12:26pm

152 Views

Post# 31069214

RE:Get Ready Gentlemen !!

Agreeed, this is call a pivot... right at the perfect time... we drop GVHD temporarly and we jump on the wagon covid with a FDA prodcut approved since 1994...

GVHD will be for later, let's get rich first....